Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Cervical Cancer Clinical Trials

115 recruiting trials for Cervical Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
115
Total Trials
115
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or...

Sponsor: Dren BioEnrolling: 9610 locations
RECRUITINGPhase 1NCT06293898

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Sponsor: SystImmune Inc.Enrolling: 28017 locations
RECRUITINGNCT07124000

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior...

Sponsor: AstraZenecaEnrolling: 10017 locations
RECRUITINGPhase 1 / Phase 2NCT07433283

Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor

Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts...

Sponsor: Sichuan Enray Pharmaceutical Sciences CompanyEnrolling: 549 locations
RECRUITINGPhase 1NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With...

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in...

Sponsor: Genentech, Inc.Enrolling: 45020 locations
RECRUITINGNCT05743517

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core...

Sponsor: Northwestern UniversityEnrolling: 1921 location
RECRUITINGPhase 2 / Phase 3NCT06851663

Trop2-targeted immunoPET Imaging of Solid Tumors

This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging...

Sponsor: RenJi HospitalEnrolling: 4001 location
RECRUITINGNCT06339827

ASk Questions in GYnecologic Oncology (ASQ-GYO)

The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient...

Sponsor: Ira WinerEnrolling: 701 location
RECRUITINGNCT05610501

Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.

In a transvaginal tru-cut biopsy, guided by ultrasound, a needle is inserted through the vaginal wall into a pelvic lesion and a few pieces of tissue are obtained for examination....

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 2004 locations
RECRUITINGPhase 1 / Phase 2NCT06814496

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with...

Sponsor: University of ArizonaEnrolling: 302 locations
RECRUITINGPhase 2NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of...

Sponsor: Daiichi SankyoEnrolling: 74020 locations
RECRUITINGPhase 3NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response...

Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for...

Sponsor: UNICANCEREnrolling: 64620 locations
RECRUITINGNCT03958240

Deciphering Mechanisms Underlying Cancer Immunogenicity

This trial is a translational, open-label, multicentric, prospective cohort study of 1100 patients aiming to describe the PD-1 (programmed death) expression in T cells (T...

Sponsor: Institut Claudius RegaudEnrolling: 11003 locations
RECRUITINGNCT02993900

Image-Guided Gynecologic Brachytherapy

This research is being done to evaluate multimodality imaging, including magnetic resonance imaging-guided therapy (MRT), as a possible treatment for gynecologic cancers. The...

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrolling: 541 location
RECRUITINGPhase 1 / Phase 2NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 2856 locations
RECRUITINGPhase 1NCT07181720

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and...

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 901 location
RECRUITINGPhase 1 / Phase 2NCT07109726

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with...

Sponsor: Terremoto Biosciences Inc.Enrolling: 20515 locations
RECRUITINGNCT07343271

Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx

The diagnostic and pre-therapeutic assessment of squamous cell carcinomas requires a neck and chest CT scan and a neck and facial MRI, which is the most effective examination, to...

Sponsor: University Hospital, Strasbourg, FranceEnrolling: 301 location
RECRUITINGNCT03702309

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor...

Sponsor: University Health Network, TorontoEnrolling: 25001 location
RECRUITINGPhase 2NCT05431764

Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

In this exploratory clinical trial, patients with newly diagnosed distant metastatic nasopharyngeal carcinoma were treated with gemcitabine+ cisplatin+PD-1 inhibitor regimen...

Sponsor: Sun Yat-sen UniversityEnrolling: 381 location
RECRUITINGNCT04859530

Automated Cervical Cancer Screening Using a Smartphone-based Artificial Intelligence Classifier

Cervical cancer remains a major public health challenge in low- and middle-income countries (LMICs) due to financial and logistical issues. The World Health Organization (WHO)...

Sponsor: Prof. Patrick PetignatEnrolling: 58861 location
RECRUITINGNCT06623500

Iodine Nutrition Status and Clinical Characteristics of Thyroid Cancer

The effect of iodine nutritional status on thyroid cancer has been controversial for many years. We designed a prospective cohort study that recruiting patients in different...

Sponsor: Shandong Provincial HospitalEnrolling: 16001 location
RECRUITINGPhase 2 / Phase 3NCT06241599

A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With...

To compare whether AK104 combined with GP or PFLL can improve survival benefit, safety and tolerability in nasopharyngeal carcinoma patients who have failed first-line treatment;...

Sponsor: Sun Yat-sen UniversityEnrolling: 3001 location
RECRUITINGPhase 1NCT06010875

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive...

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 481 location
RECRUITINGPhase 2NCT06475300

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung...

This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 5701 location
RECRUITINGPhase 2NCT06535607

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic...

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

Sponsor: AstraZenecaEnrolling: 25720 locations
RECRUITINGNCT07328243

Irreversible Electroporation for Recurrent or Metastatic Cervical Lymph Node Metastases From Thyroid Cancer: A...

This is a single-arm, open-label, multicenter, exploratory clinical trial designed to systematically evaluate the efficacy, safety, and patient benefit of ultrasound-guided...

Sponsor: Tian'an JiangEnrolling: 851 location
RECRUITINGNCT04185974

Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer

After multimodal therapy of head-and-neck tumors, patients often develop local recurrence, locally progressive disease or second primary tumors. In this highly pre-treated patient...

Sponsor: University Hospital HeidelbergEnrolling: 722 locations
RECRUITINGPhase 4NCT06457503

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic...

This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.

Sponsor: Coherus Oncology, Inc.Enrolling: 10013 locations
RECRUITINGNCT06083103

Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)

\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is...

Sponsor: Centre Paul StraussEnrolling: 501 location
RECRUITINGNCT07299474

Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures

The purpose of this study is to evaluate the efficacy of lavender aromatherapy in adult patients undergoing awake otolaryngologic procedures in the outpatient clinic setting. The...

Sponsor: Cedars-Sinai Medical CenterEnrolling: 1841 location
RECRUITINGNCT07396259

Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and...

Head and neck cancer is ranked among the fifth to eighth most prevalent cancers worldwide and is associated with a high mortality rate. Immunotherapy has been established as the...

Sponsor: Chang Gung Memorial HospitalEnrolling: 1501 location
RECRUITINGPhase 2NCT06534762

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research. The clinical...

Sponsor: Zhejiang Provincial People's HospitalEnrolling: 2601 location
RECRUITINGPhase 1NCT03114462

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 111 location
RECRUITINGPhase 2NCT07067268

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.

Sponsor: Fudan UniversityEnrolling: 761 location
RECRUITINGNCT07266363

Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma (ESCC) remains a highly lethal cancer worldwide, largely due to late diagnosis. Current screening methods such as upper endoscopy are invasive,...

Sponsor: City of Hope Medical CenterEnrolling: 6001 location
RECRUITINGNCT06676592

A Study of the Use of 3D Technology to Guide Head and Neck Surgery

The purpose of this study is to test how the new 3D technology can be used to help improve the surgeon's ability to use information from standard imaging scans to guide head and...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 277 locations
RECRUITINGPhase 1 / Phase 2NCT05941507

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1)...

Sponsor: LigaChem Biosciences, Inc.Enrolling: 3008 locations
RECRUITINGPhase 2NCT06563362

Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma

Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce...

Sponsor: University of ZurichEnrolling: 1205 locations
RECRUITINGNCT05884983

Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma

All participants will be tested for EBV-related biomarkers, including EBNA1-IgA, VCA-IgA, and BNLF2b total antibody (P85-Ab), and participants with high serologic risk will be...

Sponsor: Zhongshan People's Hospital, Guangdong, ChinaEnrolling: 120001 location
RECRUITINGPhase 1NCT05647122

First in Human Study of AZD9592 in Solid Tumors

This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each...

Sponsor: AstraZenecaEnrolling: 40320 locations
RECRUITINGNCT06443866

I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

The objective of this study is to demonstrate the clinical utility of I-124 PET/CT imaging and dosimetry in patients with thyroid cancer including 1) Evaluation of extent (volume...

Sponsor: Miami Cancer Research Center, Inc.Enrolling: 501 location
RECRUITINGPhase 1 / Phase 2NCT06128551

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C...

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated...

Sponsor: Revolution Medicines, Inc.Enrolling: 53420 locations
RECRUITINGPhase 1 / Phase 2NCT06799637

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor...

Sponsor: Evopoint Biosciences Inc.Enrolling: 35020 locations
RECRUITINGPhase 3NCT05277688

Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients

To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk...

Sponsor: Ruijin HospitalEnrolling: 3402 locations
RECRUITINGPhase 1NCT06761937

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

Patients with head and neck cancer treated with radiotherapy (RT) have a substantial change of recurrence of the tumor in the pharynx or lymph nodes in the neck. Once tumor and/or...

Sponsor: Erasmus Medical CenterEnrolling: 301 location
RECRUITINGPhase 3NCT03731442

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as...

Sponsor: Chinese Academy of Medical SciencesEnrolling: 3001 location
RECRUITINGNCT03835273

Oesophagectomy and Chest Wall and Respiratory Function

Open surgery for esophageal cancer commonly involves large incisions in the chest, associated with a high rate of pulmonary complications (30-50%). Minimally invasive approach...

Sponsor: Imperial College LondonEnrolling: 1001 location
RECRUITINGPhase 1 / Phase 2NCT06938880

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid...

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,LtdEnrolling: 601 location
RECRUITINGPhase 3NCT05674305

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA...

The goal of this multicenter randomized non-inferior study is to compare radiotherapy alone versus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma...

Sponsor: Fudan UniversityEnrolling: 3661 location

Showing 50 of 115 trials.Search all Cervical Cancer trials

Frequently Asked Questions

There are currently 115 clinical trials for Cervical Cancer, with 115 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Cervical Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Cervical Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

The this entity record above pulls directly from the NIH ClinicalTrials.gov registry. What follows is the per-entity context — how this entity sits in the broader U.S. clinical trials and research registries distribution and which underlying factors drive the headline numbers.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.